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ABSTRACT OF THE DISSERTATION
Electrophysiology of the Inner Retina in Health and Disease:
EAAT5 in the Rod Bipolar Cell and Oscillatory Potentials in Diabetes
by
Gregory W. Bligard
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2020
Professor Peter D. Lukasiewicz, Chair
The inner retina is a highly tractable location for the study of neural networks in the central
nervous system and improving our understanding of the inner retina is important for the
treatment of a number of ophthalmic diseases. This dissertation aims to improve understanding
of the inner retina in two parts: first, a basic neuroscientific project concerning normal neuronal
processing in the inner retina at a cellular level, and second, a translational ophthalmologic
project regarding the development in the inner retina of a common disease.
In mammals, modulation of the amplitude of dim visual signals primarily occurs at axon
terminals of rod bipolar cells. While such effects are largely mediated by conventional inhibitory
neurotransmitter receptors, excitatory amino acid transporter 5 (EAAT5) also contributes a
significant unconventional inhibitory activity. EAATs clear glutamate from the synapse, but they
also have an intrinsic glutamate-gated chloride conductance. EAAT5 in particular has very little
glutamate reuptake activity, and primarily acts as an inhibitory glutamate-gated chloride channel.
In my primary project I demonstrate the relative contribution of EAAT5-mediated inhibition
onto rod bipolar cells in response to physiologically relevant stimuli in retinal slice explants. In
ix

this setting, I also compare the roles of autoinhibition, in which excitation of the cell leads to
inhibition onto itself, and alloinhibition, which is driven by other bipolar cells. Contrary to prior
reports, I found that EAAT-mediated inhibition can be elicited by dim light stimuli. I also found
that while conventional inhibitors mediate nearly all alloinhibition onto rod bipolar cells, EAAT5
is the primary mediator of rod bipolar autoinhibition. Finally, in silico modeling demonstrates
that EAAT5-mediated autoinhibition may have a substantial impact on postsynaptic excitation of
the downstream AII amacrine cell. My combined results suggest that EAAT5 autoinhibition in
rod bipolar cells modulates the rod signaling pathway, possibly tuned to prevent long-term
changes in baseline depolarization while still allowing single-photon signals to pass in the dark
and transient signals to pass in the twilight.
Obesity predisposes humans to type 2 diabetes, which may result in diabetic retinopathy,
commonly understood to be fundamentally a vascular pathology. In my secondary project I seek
to characterize the course of electroretinographic dysfunction in a high-fat diet–induced model of
diabetes in mice. Mice weaned to chow or to a high-fat diet were tested for electroretinographic
dysfunction at 3, 6 and 12 months of age. There is no evidence of microvascular disease in these
mice until 12 months. However, at as early as 6 months, high fat–fed mice demonstrated
increased latencies and reduced amplitudes of oscillatory potentials compared with controls.
These electroretinographic abnormalities were correlated with glucose intolerance. The results
suggest that retinal disease in the diabetic milieu may progress through neuro-retinal stages long
before the development of vascular lesions representing the classic hallmark of diabetic
retinopathy, establishing a model for assessing novel interventions to treat eye disease.
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Chapter 1: Background and Introduction
1.1 The Neural Circuitry of the Inner Retina
The retina has long served as an experimentally tractable location for the study of the central
nervous system, due in part to its physical accessibility, its relatively simple circuitry compared
to the brain, and its precise, layered organization (Figure 1.1) [1]–[3]. Nevertheless, the
vertebrate retina is still a complex neural network, and significant neuronal processing and
filtering of visual information takes place in the retina itself before any visual signal even
reaches the optic nerve [4]–[12].

Figure 1.1: The retina is a well-organized, laminar structure composed of five distinct classes of neurons.
(Figure from [1].) Photoreceptors (PR) are hyperpolarized by light and synapse onto bipolar cells (BC) and
horizontal cells (HC) in the outer plexiform layer (OPL). Bipolar cells then synapse onto ganglion cells (GC) and
amacrine cells (AC) in the inner plexiform layer (IPL).

Visual signaling begins with rod and cone photoreceptors, which continuously depolarize in
darkness and release glutamate [13], [14]. Following the absorption of a photon, photoreceptor
1

opsins, acting via a G-protein-coupled receptor (GPCR) signal cascade, can close membrane
channels, hyperpolarize the cell, and decrease glutamate release [15]–[17]. Photoreceptors
transmit this information in parallel onto bipolar cells at synapses in the outer plexiform layer
(OPL) [13]. Cone bipolar cells come in a number of varieties [18], but two main classes: in
response to glutamate, OFF cone bipolar cells depolarize via ionotropic AMPA or kainate
receptors [19], whereas ON cone bipolar cells hyperpolarize via sign-inverting metabotropic
mGluR6 receptors [20]. Visual information passes from cone bipolar cells to ganglion cells via
glutamatergic neurotransmission in the inner plexiform layer (IPL) [21]–[23], and from there,
ganglion cell axons form the optic nerve, which passes visual information to the brain [24], [25].
Meanwhile, rods only synapse onto a single type of rod bipolar cell, which also receives its input
via the mGluR6 metabotropic receptor [26]. Rod bipolar cells, in turn, synapse in the IPL onto
AII amacrine cells [27]–[30]. Rod and cone pathways converge where AII amacrines make gap
junctions with ON cone bipolar cells and glycine-mediated inhibitory synapses onto OFF cone
bipolar cells (Figure 1.2) [31]–[33]. Additional lateral communication and signal modulation
between these pathways takes place through horizontal cells at the OPL and many forms of
amacrine cells in the IPL [34]–[40].
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Figure 1.2: Rod pathways in the mouse retina utilize cone circuitry.
(Figure from [33].) Rods synapse onto a single class of rod bipolar cell, which synapses onto the AII amacrine cell.
The AII generates parallel streams of ON and OFF by forming excitatory electrical synapses with ON cone bipolar
cells and inhibitory glycine synapses with OFF cone bipolar cells, respectively.

Astoundingly, this neural network is capable of interpreting visual stimuli presented over more
than 12 orders of magnitude of ambient luminance [41], [42], a feat that is only possible with
sophisticated neuronal gain control systems. Such flexibility is achieved in part by a transition
from rod-mediated vision in darkness to cone-mediated vision in bright light [43], [44], but rod
vision alone still operates over a luminous range that far exceeds the dynamic range that
ganglion cells would be capable of encoding without mechanisms for signal gain control. Gain
modulation is attributable both to adaptation within photoreceptors themselves as well as to
adaptation of the neural network downstream of the photoreceptors [45]–[50]. Our understanding
3

of primary photoreceptor adaptation has become quite sophisticated, but the mechanisms behind
retinal network adaptation are less well understood [51].

1.2 Excitatory Amino Acid Transporters
Ion channel gating and neurotransmitter transport are mechanistically distinct processes that are
typically performed by separate proteins. Ion channels are pores that allow the diffusion of ions
along preexisting electrochemical gradients, while neurotransmitter transporters actively pump a
substrate against its electrochemical gradient [52]. There are, however, a few novel
neurotransmitter transporters that can also act as ion channels, including known transporters for
dopamine, GABA, glutamate, norepinephrine, proline, and serotonin [53]–[61].
The excitatory amino acid transporters (EAATs) are one such family of neurotransmitter
transport proteins. EAATs are members of the solute carrier family 1 (SLC1), which also
includes two neutral amino-acid transporters, ASCT1 and ASCT2 [62], and are distinct from
vesicular glutamate transporters. The EAAT family is best known for those members that act to
terminate signaling in the CNS by removing released glutamate from synapses following
neurotransmission. However, in certain members of the EAAT family, glutamate binding can
instead open a chloride conductance through the transporter that suppresses synaptic activity,
although its role in CNS signaling is poorly understood [63], [64].
Five mammalian EAATs have been discovered and are designated EAAT1 through EAAT5
[64]–[66]. EAAT1, also known as SLC1A3 and GLAST1 (glutamate aspartate transporter 1)
[67], is present in glial cells throughout the central nervous system and at high levels in
Bergmann glia of the cerebellum. EAAT2, also known as SLC1A2 and GLT1 (glutamate
transporter 1) [68], is almost exclusively glial, and is widespread and highly abundant throughout
4

the central nervous system. EAAT3, also known as SLC1A1 and EAAC1 (excitatory amino acid
carrier 1) [69], is present in neurons throughout the CNS. EAAT4 (SLC1A6) is found in
cerebellar Purkinje cells and in the forebrain [62], [70]–[72]. EAAT5 (SLC1A7) is localized to
rod photoreceptors and rod bipolar cells in the retina [65], [73].

Figure 1.3: EAATs are both glutamate transporters and chloride channels.
(Figure from [74].) A schematic diagram of an EAAT is shown. Glutamate is co-transported with three Na+ and one
H+, along with the counter-transport of one K+. Glutamate and Na+ also activate a stoichiometrically uncoupled
chloride conductance.

The two functions of these proteins are not thermodynamically coupled. The rate of glutamate
uptake is independent of chloride concentration, instead dependent on the cotransport of three
sodium ions and one proton and the counter-transport of one potassium ion (Figure 1.3) [75].
Meanwhile the transporter’s chloride conductance is dependent on glutamate and sodium binding
to the transporter, as well as membrane potential, but is thermodynamically independent of the
rate or direction of glutamate transport (27-31) [76]–[81]. In addition, the balance between these
two functions varies enormously between individual members of the EAAT family [82], [83].
EAAT1, EAAT2, and EAAT3 have little chloride conductance and play an important role in
glutamate reuptake in the cells that express them [84], [85]. EAAT4 and EAAT5 have little
5

glutamate uptake activity, but instead play a novel role as a presynaptic inhibitory signaling
mechanism in the cerebellum and retina, respectively [64], [86].

1.3 Electroretinography in Diabetic Retinopathy
Diabetic retinopathy is an end-organ complication of diabetes mellitus and is a leading cause of
blindness worldwide [87], [88]. It can take many years for a diabetic patient to develop
symptoms of retinopathy, but patients can progress quite rapidly to blindness once symptoms
appear [89]. In many ways current treatments are inadequate, and there is a critical need for a
better understanding of the basic pathogenic mechanisms of this disease.
The traditional understanding of diabetic retinopathy is that the metabolic defects of diabetes
cause microvascular damage, inflammation, and loss of endothelial integrity in the retina. These,
in turn, lead to grossly detectable changes such as microaneurysms, hemorrhages, macular
edema, and vascular proliferation which all finally lead to neuronal damage in the inner retina
and loss of vision. Thus, diabetic retinopathy is treated clinically with drugs and procedures
aimed at reducing vascular leakage, proliferation, and edema. However, deficits in the oscillatory
potential (OP) component of the electroretinogram (ERG) have been observed by a number of
researchers in the retinas of patients prior to visible microvascular defects [90]–[93]. In fact,
patients with diabetes but without funduscopic retinopathy were found with decreased OP
amplitudes as early as 1962 [94]. Collectively, these studies suggest that functional changes may
actually occur before vascular pathology.
In the clinic, however, diabetic patients are still typically first seen and treated when they present
with signs and symptoms attributable to retinal vascular pathology; electrophysiological visual
testing is not regularly used to assess diabetic patients [95], [96]. Thus, a better understanding of
6

the neuronal deficits in the early-stage diabetic retina is ripe for clinical benefit; the identification
of early functional changes might actually allow the prevention of later vascular pathologies
before they even occur.

1.4 Objectives of the Dissertation
This thesis is intended to improve our understanding of the neural circuitry of the inner retina as
a project in two independent parts. In the first and larger part, presented in Chapter 2, I have
focused on a basic scientific question relating to retinal network signal modulation. Recently,
evidence has arisen that an amino acid transporter, EAAT5, plays a substantial role in this
inhibitory process. In Chapter 2, I present the results of experiments designed to expand our
understanding of the novel role of this protein in inner retinal visual processing. Specifically, I
begin by correcting a previously-published theory regarding the circumstances under which
EAAT5 inhibition is actually active. I then examine whether EAAT5 primarily mediates
autoinhibition or alloinhibition in rod bipolar cells, a question for which evidence supporting
both possibilities had previously existed. Finally, I demonstrate the functional significance of
EAAT5-mediated inhibition on visual processing.
Revealing the function and mechanisms behind EAAT5-driven inhibition in retinal circuitry will
not only fill the gaps in our understanding of visual processing but will also undoubtedly
improve our understanding of neural circuit modulation in general, including a better
understanding of the many roles that EAAT-mediated inhibition may play in other parts of the
CNS. In addition, a better understanding of retinal circuitry is needed to elucidate the
mechanisms underlying common eye diseases like macular degeneration, retinitis pigmentosa,
congenital blindness, and diabetic retinopathy. In the second part of this dissertation, presented in
Chapter 3, I shift focus from basic science to such a disease, concentrating in particular on the
7

neuronal effects of the early stages of diabetic retinopathy on the inner retina. Specifically, I
present an analysis of electroretinograms (ERGs) recorded from high-fat diet (HFD) and control
mice over 12 months. In so doing, I characterize the ERG changes that take place as diabetic
retinopathy develops and demonstrate that despite the traditional understanding of diabetic
retinopathy, electrophysiological deficits actually precede structural lesions in these mice.
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Chapter 2: The Glutamate Transporter
EAAT5 Mediates Rod Bipolar Cell
Autoinhibition
2.1 Background
The retina is capable of responding to visual stimuli over more than 12 orders of brightness
magnitude [41], [42], necessitating substantial gain modulation of neural signals to avoid
response saturation and maintain sensitivity. In the rod pathway, gain modulation occurs
primarily at the synapse between the rod bipolar and the AII amacrine cell [97]. It has long been
understood that, in response to presentation of light stimuli, a variety of amacrine cell
populations release GABA and glycine onto rod bipolar cell axon terminals, which activate
GABAA, GABAC, and glycine receptors, evoking an inhibitory chloride conductance [98]–[106].
These conventional inhibitors mediate both autoinhibition, in which excitation of the cell leads to
feedback inhibition onto itself, and alloinhibition, in which inhibition is driven by other bipolar
cells and occurs independently of the activity of the cell of interest. Specifically, conventional
autoinhibition of the rod bipolar cell is mediated via the A17 amacrine cell reciprocal synapse
while conventional alloinhibition is mediated via various lateral amacrine cell pathways (Figure
2.1) [107], [108].

9

Figure 2.1: Conventional inhibition is mediated by a variety of sources.
Rod bipolar cells receive presynaptic GABA-mediated autoinhibition from A17 amacrine cells and additional
presynaptic alloinhibition from other GABAergic and glycinergic amacrine cells.

However, in addition to conventional inhibitors, rod bipolar cells are also subject to a presynaptic
inhibition mediated by excitatory amino acid transporter 5 (EAAT5) [65]. Transporters in the
EAAT family are thusly named for their role in removing glutamate from synapses following
neurotransmission. Glutamate binding to EAATs can also open a chloride conductance through
the transporter that suppresses synaptic activity [63], [64]. These two functions are not
stoichiometrically coupled; the rate of glutamate uptake is independent of chloride concentration,
while the transporter’s chloride conductance is dependent on glutamate, sodium, and membrane
potential [76], [77]. In addition, the relative activity of each of these two functions varies greatly
between individual members of the EAAT family [82], [83].[63], [64][62], [63][53], [54] For
example, while EAAT1, EAAT2, and EAAT3 have little chloride conductance and play an
important role in glutamate reuptake in the cells that express them [84], [85], EAAT4 and
EAAT5 play a significant role in presynaptic inhibition but little role in glutamate uptake [86],
[109]. Compared to other forms of presynaptic inhibition, EAAT5-mediated inhibition has slow
10

kinetics, with a decay time constant of around 130 ms, as opposed to 34 ms for GABACR- or 2
ms for GABAAR-mediated inhibitory currents [110], [111]. In the retina, EAAT5 is expressed in
the axon terminals of photoreceptors and rod bipolar cells [112].
Wersinger et al. demonstrated that rod bipolar EAAT5 can mediate autoinhibition, since
glutamate release from the cell of interest can evoke EAAT5-mediated currents at its own
synaptic terminal [112]. It has also been shown that EAAT5-mediated alloinhibition is possible,
because glutamate spillover from neighboring rod bipolars can evoke EAAT5 currents [113].
However, both of these studies either used nonphysiological electrical stimulation of cells or
bath-applied antagonists of conventional inhibition. Previous work suggested that the mode of
presynaptic inhibition onto rod bipolar cells switches from conventional inhibitors to EAAT5mediated inhibition as a function of the intensity of the light stimulus, and there has been
speculation that EAAT5 inhibition mediates light adaptation in the rod pathway [111]. In
response to light, the depolarizing response of rod bipolar cells is limited by inhibitory
neurotransmitters [114], and exogenous blockade of GABA and glycine is known to upregulate
glutamate release from bipolar cells [99], [115], so the degree to which auto- or alloinhibition is
important under physiologically-relevant conditions remains unknown (Figure 2.2). Currently,
neither the source of glutamate that activates EAAT5 in the rod bipolar cell, nor the function of
this transporter in visual processing is clear.
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Figure 2.2: EAAT5-mediated presynaptic inhibition is gated by glutamate and has two potential sources
indicated by the numbered red arrows: 1) autoinhibitory glutamate released from the rod bipolar of interest onto
itself and 2) alloinhibitory glutamate released from neighboring rod bipolar cells.

In this chapter, I investigate these questions. I first show that both forms of inhibition occur at all
light intensities, suggesting that the mode of inhibition does not switch across light intensities in
the manner previously described. I then show that although EAAT5 is not a significant
contributor to alloinhibition, it is the main source of autoinhibition to rod bipolar cells. Finally,
in-silico modeling of the rod bipolar – AII amacrine cell synapse shows that EAAT5-mediated
autoinhibition has a substantial effect on synaptic transmission and may be important in
maintaining rod bipolar cell signaling within the sensitive region of the synaptic activation curve.

2.2 Materials and Methods
2.2.1 Animal Protocols
Animal protocols were approved by the Washington University School of Medicine Animal
Studies Committee.
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2.2.2 Retinal Dissection
Mice of either sex (28 – 60 days of age; C57BL/6J strain; The Jackson Laboratory) were darkadapted overnight and sacrificed using carbon dioxide. The retina was isolated, and 400 µm slice
preparations were made from the dorsal retina. All dissection procedures were performed in
complete darkness under infrared illumination. Dissection medium (see section 2.2.5 Solutions
and Drugs) was continuously oxygenated. Retinal preparations were stored in an oxygenated
dark box at room temperature until experimental use. Dissections were performed from 10 to 11
am, and recordings were always performed in the afternoon.

2.2.3 Whole-Cell Recordings
Whole-cell patch recordings were made from bipolar cell somata in retinal slices by viewing
them with an upright microscope under infrared illumination. The sample chamber was curtained
to prevent light leakage from infrared eyepieces reaching the samples. Extracellular media was
continuously applied to the samples via a preheated perfusion system positioned near the slice
preparation. Electrodes were made from borosilicate glass with a P97 Flaming/Brown puller
(Sutter Instruments) and had resistances of approximately 5 MΩ. All recordings were made at
30°C. Signal software (Cambridge Electronic Design) was used to generate electrical command
outputs and acquire and store data. Recordings were sampled at 5 kHz and filtered at 2 kHz with
the four-pole Bessel filter on the Axopatch 200B (Molecular Devices). Liquid junction potentials
were corrected at the beginning of each recording. Depending on the experiment, cells were
either voltage clamped at 0 mV, the reversal potential for nonselective cation channels, isolating
Cl- currents, or were held at -60 mV with ECl at 0 mV. In the latter case, the mGluR6-mediated
cation currents ran down quickly and did not contaminate the Cl- currents.
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2.2.4 Morphological Identification
Sulforhodamine B (0.005%) was included in the intracellular solution for all recordings to
identify the cell type and to confirm correct placement of puff pipettes at the rod bipolar axon
terminal. After electrophysiological recordings were finished, cells were morphologically
identified by their axon terminal ramification morphology and location in the inner plexiform
layer (IPL) (Figure 2.3) [116], [117].

Figure 2.3: Differential interference contrast photomicrograph of a pipette and rod bipolar cell (RBC)
filled with fluorescent dye (Sulforhodamine B 0.005%) following whole-cell recording in a retinal slice.

2.2.5 Solutions and Drugs
Retinal dissections were performed in HEPES-buffered extracellular Ringer’s solution
containing (in mM): 137 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl, 28 glucose, 10 HEPES, 4 Na-Llactate, 2 Na-pyruvate, 0.5 L-glutamine, adjusted to pH 7.4 by NaOH. Physiological recordings
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were performed in bicarbonate-buffered extracellular solution containing (in mM): 125 NaCl, 2.5
KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 20 glucose, 1.25 NaH2PO4,4 Na-L-lactate, 2 Na-pyruvate,
0.5 L-glutamine. Extracellular solutions were continuously aerated with 95% O2 and 5% CO2
and the pH was 7.4 at 30°C. For experiments in which cells were held at 0 mV the intracellular
solution was (in mM): 120 CsOH, 120 D-gluconic acid, 1 CaCl2, 1 MgCl2, 11 EGTA, 10 NaHEPES, 10 TEA-Cl, 5 ATP-Mg, 1 GTP-Na, adjusted to pH 7.2 by CsOH. For experiments in
which cells were held at -60 mV, the intracellular solution was (in mM): 125 CsCl, 25 HEPES,
10 TEA-Cl, 0.5 EGTA, 2.5 ATP-Mg, 2.1 GDPβS, adjusted to pH 7.2 by CsOH.
When bath-applied, conventional inhibitory receptor antagonists were the GABAA receptor
antagonist (–)-bicuculline methobrimide (50 µM), GABAC receptor antagonist (1,2,5,6Tetrahydropyridin-4-yl)methylphosphinic acid hydrate (TPMPA) (50 µM), and glycine receptor
antagonist strychnine (1 µM). When puff-applied, the concentrations used were 250 µM
bicuculline, 250 µM TPMPA, and 5 µM strychnine. Puff-applied glutamate was at concentration
2.5 mM. EAATs were blocked with DL-threo-β-benzyloxyaspartic acid (TBOA) (50 µM
extracellularly or 3 mM intracellularly). Excitatory glutamate receptors were generally not
targeted pharmacologically, except in Figure 2.10, when AMPA and NMDA receptors were
blocked by bath application of 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate
(CNQX, 5 µM), and D-(–)-2-amino-5-phosphonopentanoic acid (D-AP5, 50 µM), respectively.
Puff-applied drugs were dissolved in a HEPES-buffered extracellular solution identical to the
one used for retinal dissections, loaded into pipettes similar to those used for patch recordings,
and were puffed onto rod bipolar cell terminals using a Picospritzer II (Parker Hannifin). Bathapplied drugs were dissolved into the recording solution described above and aerated using the
same source of gas and perfused into the recording chamber using the same delivery system as
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the control solution. Drugs were given at least 4 minutes to perfuse into and be washed out of the
chamber before the next round of recordings, and therefore experiments with bath-applied drugs
were performed in batches; otherwise, the order of experiments was randomized.

2.2.6 Light Stimulation
Full-field light stimuli were generated using a 505 nm LED projected through the optical path of
the microscope, passing through a diffusion filter to ensure even lighting over the entire field and
a wide enough lens to illuminate the entire retinal slice. Coarse control of the light intensity was
achieved by inserting neutral-density filters of varying strength into the optical path. Fine control
of light intensity was achieved by varying the current through the LED.

2.2.7 Data Analysis
Charge transfer was measured using the area function in Signal, and difference in charge transfer
was calculated by simple subtraction. Standard errors of the mean (SEMs) for difference in
charge transfer were calculated by addition of root mean squares of SEMs of the underlying
charge transfers. P-values were calculated using two-tailed t-tests. In experiments comparing the
same conditions across multiple light intensities, corrections for multiple comparisons were
made using the Holm–Bonferroni method.

2.2.8 Modeling
The rod-bipolar to AII-amacrine cell synapse was simulated in NeuronC [118]. Each cell was
modeled as a sphere (diameter 4 µm), and each cell’s membrane was modeled as a first-order
resistor-capacitor circuit. The rod bipolar cell explicitly included voltage-dependent calcium
channels (L-type, non-inactivating, 8 mS/cm2) and calcium pumps (Vmax = 20 nA/cm2, Km = 20
µM, non-electrogenic). Calcium diffused through radial shells (n = 10) to and from an internal
core. All other gated and non-gated channels were represented by the global membrane
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resistance of the rod bipolar cell, which was calibrated to match our experimental data (Rm = 400
Ω-cm2). Rod bipolar cell membrane capacitance was set to calibrate the membrane time constant
(40 ms, Cm = 100 µF/cm2). The synapse itself was simulated by a series of filters that defined the
transfer function for vesicle release and a temporal impulse function (release rate proportional to
[Ca], tau = 2 ms), as well as the size of the readily-releasable pool (20) and its replenishment rate
(50 Hz). For simplicity, release was set to be noiseless, i.e. only the average rate was simulated.
The postsynaptic currents were generated by binding of the simulated glutamate release to a
sequential-state Markov model of a non-desensitizing AMPA receptor/channel. A current clamp
in the rod bipolar was driven by pre-recorded data from the experiments on real rod bipolar cells,
and a voltage-clamp in the AII (Rm = 100 MΩ-cm2, Cm = 1 µF/cm2) was set to the membrane
resting potential (-70 mV) to record post-synaptic currents. The presynaptic [Ca2+] was plotted
from the Ca2+ diffusion shell closest to the simulated cell membrane.

2.3 Results
2.3.1 The Mode of Retinal Presynaptic Inhibition Does Not Switch with Light
Intensity.
Light stimuli evoke inhibitory Cl- currents on rod bipolar axon terminals that are mediated by a
combination of amacrine cell activation of GABA and glycine receptors and glutamate-driven
activation of EAAT5 [98], [111]. I investigated the relative contribution of each of these
pathways in response to light stimuli. Unexpectedly, however, GABAA, GABAC, and glycine
receptor antagonists reduced inhibition only minimally in response to dim stimuli, while further
addition of EAAT5 antagonist TBOA [119] blocked such inhibition to a greater degree (Figure
2.4).
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Figure 2.4: Example RBC IPSCs.
Inhibitory post-synaptic currents (IPSCs) evoked by a brief (200 ms) flash of light from a rod bipolar cell (RBC)
voltage clamped at 0 mV and bath-applied inhibitory receptor antagonists are shown. RBC IPSCs evoked by a dim
flash of light (400 photons/µm2/s) from a black background were blocked very little by a mixture of GABA and
glycine (gly) blockers (50 µM bicuculline, 50 µM TPMPA, 1 µM strychnine). Subsequent addition of the EAAT
antagonist TBOA (50 µM) blocked the current.

In response to bright light stimuli, bath application of GABA and glycine receptor blockers
significantly reduced inhibition onto rod bipolar cells, but additional bath application of TBOA
blocked the inhibitory response further (Figure 2.5). These results differ from earlier work
suggesting that in the dark-adapted retina, low-intensity light stimuli elicit presynaptic inhibition
onto rod bipolar cells mediated by GABA and glycine, while high-intensity light stimuli fail to
elicit GABA- or glycine-mediated inhibition, and instead elicit EAAT5-mediated inhibition
[111]. My results are not consistent with this hypothesis of an inhibitory switch.
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Figure 2.5: The mode of light-evoked inhibition to rod bipolar cells does not depend on light intensity.
Inhibitory post-synaptic currents (IPSCs) were evoked by a brief (200 ms) flash of light from bipolar cells voltage
clamped at 0 mV and bath-applied inhibitory receptor antagonists. Normalized inhibitory response by light intensity
for RBCs is shown. All stimuli were presented in the context of a zero-light background. Conventional inhibitory
receptor blockers (open circles) had minimal effect at any light intensity compared to controls (filled circles), while
TBOA (filled triangles) caused a significant reduction in inhibition at all light intensities above 10 ph./µm2/s. (n = 43
cells) Error bars indicate SEM. * indicates p-value < 0.05.

The EAAT5-mediated current was unique to rod bipolar cells, as conventional inhibitory
blockers eliminated all inhibition to cone bipolar cells (Figure 2.6). This validates previous work
and is consistent with the finding that EAAT5 is found in rod but not cone bipolar cells [111],
[112]. All of these experiments were performed in dark-adapted retinas, and the dimmest stimuli
that elicited an inhibitory response in either rod or cone bipolar cells were below cone sensitivity,
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suggesting that rod input can contribute inhibition onto cone pathways in response to dim stimuli
[120], [121].

Figure 2.6: Inhibition onto cone bipolar cells is exclusively conventional.
Inhibitory post-synaptic currents (IPSCs) are evoked by a brief (200 ms) flash of light from bipolar cells voltage
clamped at 0 mV and bath-applied inhibitory receptor antagonists. Normalized inhibitory response by light intensity
for cone bipolar cells is shown. All stimuli were presented in the context of a zero-light background. Conventional
inhibitory receptor blockers alone (open circles) completely ablated the inhibitory response compared to controls
(filled circles). (n = 4 cells) Error bars indicate SEM. * indicates p-value < 0.05.

2.3.2 GABA and Glycine Mediate Alloinhibition onto Rod Bipolar Cells.
I was surprised by the capacity of bath-applied TBOA to block inhibitory responses to such a
significant extent in rod bipolar cells. Others have shown that when presynaptic inhibition is
blocked at bipolar cell terminals, downstream excitatory post-synaptic currents are enhanced
[99], [115]. I considered that the simultaneous bath-application of GABA and glycine receptor
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blockers may have disinhibited cells throughout the network, causing abnormally high synaptic
activity in neighboring bipolar cells, potentially leading to artificially enhanced EAAT5mediated inhibition via glutamate spillover. To test this possibility, I measured the light-evoked
inhibitory response in the presence and absence of intracellular TBOA applied through the
recording pipette [111], and in the presence or absence of a puff application of GABA and
glycine receptor blockers on the axon terminal (Figure 2.7).

Figure 2.7: Cartoon depicting intracellular and puff application of receptor antagonists.
Diagram illustrates experimental paradigm to limit network effects of drug application. RBCs were recorded in the
presence and absence of intracellular TBOA (3 mM) in the recording pipette, while a second puff pipette with
conventional inhibitor antagonists (250 µM bicuculline, 250 µM TPMPA, 5 µM strychnine) was targeted at the axon
terminal.

In the presence of puff-applied GABA and glycine antagonists, rod bipolar cells demonstrated
substantial reduction of inhibition in response to light (Figure 2.8). In fact, conventional
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inhibitory blockers significantly reduced inhibitory input when puff-applied, regardless of the
presence or absence of intracellular TBOA.

Figure 2.8: Puff application of GABA/glycine blockers successfully blocks the light-evoked IPSC.
A rod bipolar cell was voltage clamped at 0 mV and a 30 ms flash of light (106 ph./µm2/s) was given in the presence
(gray) and absence (black) of a puff starting 100 ms before the onset and ending 100 ms after the offset of light.

In contrast, internal application of TBOA had no significant effect on the amount of inhibition
onto rod bipolar cells (Figure 2.9).
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Figure 2.9: Results of intracellular and puff application of receptor antagonists.
Puff application of GABA/glycine antagonists (dark bars) blocks light-evoked IPSCs compared to controls (white
bars) while intracellular TBOA (left) has no significant effect compared to controls (right). RBCs were voltage
clamped at 0 mV (n = 12 cells). Error bars indicate SEM. * indicates p < 0.05.

To confirm that intracellular TBOA in my preparation was capable of blocking glutamatemediated inhibition, I tested the responses of control and TBOA-filled rod bipolars to glutamate
puff application at the axon terminal and demonstrated that internal TBOA reduced the responses
to puffs of glutamate (Figure 2.10). Overall, these results indicate that conventional inhibitors,
but not EAAT5, mediate alloinhibition onto rod bipolar cells, in agreement with previous studies
[98]–[100].
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Figure 2.10: Intracellular application of TBOA blocks the response to glutamate.
RBCs with (grey) and without (black) intracellular TBOA were voltage clamped at -60 mV with ECl = 0 and 5 µM
CNQX and 50 µM D-AP5 bath-applied to block AMPA and NMDA receptors, then subjected to a brief 2.5 mM
glutamate puff. Left: two example traces. Right: charge transfer for each category. (n = 8 cells) Error bars indicate
SEM. * indicates p < 0.05.

2.3.3 EAAT5 Mediates Autoinhibition onto Rod Bipolar Cells.
Usage of a static voltage clamp paradigm in which the cell was clamped at a fixed voltage had
prevented the activation of voltage-gated calcium channels in the cell of interest, blocking
excitatory output and therefore blocking any type of autoinhibition in my recordings. Thus, I
developed a moving voltage clamp experiment in order to test the extent of EAAT5-mediated
autoinhibition under physiologically relevant conditions. I applied to rod bipolar cells a voltage
pulse input modeled to duplicate the excitation pattern of a rod bipolar cell in response to a light
pulse of matching intensity and duration [114] (Figure 2.11). The initial current responses from
such traces would necessarily include leakage currents changing in response to the shift in
voltage, meaning that raw amplitudes would not be informative. However, by comparing
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responses from the same cell in the presence and absence of a given extracellularly-applied
inhibitory receptor antagonist, the difference between the two responses could measure the
relevant level of inhibition. I also measured the alloinhibitory responses of these cells via a fixed
voltage and stimulation with light, to better facilitate direct comparison between auto- and
alloinhibition under comparable conditions of resting membrane potential and ECl.

Figure 2.11: Voltage pulse input.
Input was modeled to mimic the excitatory profile of an RBC in response to the light stimuli used in this chapter
based on data in [114].

In this manner, I compared the autoinhibitory response of rod bipolar cells in the presence and
absence of conventional inhibitory blockers and observed small but measurable levels of GABAand glycine-mediated inhibition (Figure 2.12).
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Figure 2.12: Voltage pulse example traces with and without GABA/gly blockers.
RBCs stimulated from a baseline of -60 mV with the voltage pulse pictured in Figure 2.11 without (grey) and with
(black) 2 s puff application of GABA/gly blockers. GABA/gly blockers elicited a small but measurable difference
that could be attributed to autoinhibition from conventional inhibitory sources. ECl = 0 mV.

Meanwhile, the difference between TBOA and TBOA-free responses demonstrated that EAAT5
plays a substantial role in autoinhibition (Figure 2.13).
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Figure 2.13: Voltage pulse example traces with and without TBOA.
RBCs stimulated from a baseline of -60 mV with the voltage pulse pictured in Figure 2.11 without (grey) and with
(black) extracellular application of TBOA. TBOA elicited a larger difference than conventional blockers that could
be attributed to autoinhibition from EAAT5. ECl = 0 mV.

Overall, these results allow us to make direct comparisons, painting a more complete picture of
the extent to which each source of inhibition impacts rod bipolar cells in response to
physiologically-relevant stimuli. They demonstrate that autoinhibition onto rod bipolar cells is
mediated by both conventional channels and by EAAT5, but that EAAT5 is the most significant
mediator of autoinhibition (Figure 2.14, left). At the same time, they also confirm that EAAT5
does not play any significant role in alloinhibition, which is largely mediated by conventional
GABA and glycine receptors (Figure 2.14, right).
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Figure 2.14: EAAT5 is the primary mediator of autoinhibition in RBCs.
ECl = 0 mV. Left: Summary data for autoinhibition experiments depicted in Figures 2.12 and 2.13. Data represents
the difference in charge transfer between two comparator conditions in individual cells. GABA/glycine-mediated
autoinhibition and EAAT5-mediated autoinhibition were significantly different from each other and were also each
significantly different from zero. (n = 24 cells) Right: Summary data for alloinhibition experiments. RBCs were held
at -60 mV and flashed for 100 ms at 105 ph./µm2/s. TBOA was present or absent in the intracellular media. GABA
and glycine blockers were puff-applied. Data represent the difference in charge transfer between populations of
cells. GABA/glycine mediated alloinhibition was significantly different from both EAAT5-mediated alloinhibition
and from zero. EAAT5-mediated alloinhibition was not significantly different from zero. (n = 10 cells) Error bars
indicate SEM. * indicates p < 0.05.

To demonstrate that the difference between the TBOA and TBOA-free traces in my
autoinhibition experiments was strictly attributable to glutamate release from the cell of interest,
I performed two control experiments. In the first, I held the cell at a reduced baseline of -100
mV, while applying a stimulus of the same amplitude, duration, and shape as before, in order to
keep the cell below the threshold for synaptic activation (Figure 2.15). In the second, I
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depolarized the cell to zero potential for an extended period of time, and then briefly returned the
cell to -60 mV and applied the standard stimulus, aiming to deplete the readily-releasable vesicle
pool prior to stimulation (Figure 2.16).

Figure 2.15: EAAT5-mediated autoinhibition is dependent on synaptic activation.
A rod bipolar cell was stimulated from a baseline of -100 mV with the voltage pulse in Figure 2.11, without (grey)
and with (black) extracellular application of TBOA. A lack of TBOA-sensitivity confirms that the autoinhibition
attributed to EAAT5 is dependent on synaptic activation.
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Figure 2.16: EAAT5-mediated autoinhibition is dependent on glutamate release.
A rod bipolar cell was stimulated from a baseline of -60 mV with the voltage pulse in Figure 2.11 immediately
following depolarization to -30 mV for 60 s. Lack of TBOA-sensitivity confirms that EAAT5-mediated
autoinhibition is dependent on vesicle release.

In both cases, the TBOA-blockable effect was completely abolished (Figure 2.17), confirming
that the observed role of EAAT5 in autoinhibition is dependent on synaptic vesicle release.
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Figure 2.17: EAAT5-mediated autoinhibition is dependent on synaptic activation and glutamate release: Summary
data representing the difference in charge transfer between two comparator conditions in individual cells is shown.
No stim indicates a cell held at -60 mV without applying a voltage stimulus. “Stim,” “-100 mV baseline stim,” and
“depolarization before stim” indicate experiments depicted in 2.13, 2.15 and 2.16, respectively. (n = 24 cells) Error
bars indicate SEM. * indicates p < 0.05.

2.3.4 EAAT5 Inhibition Modulates Signaling to AII Amacrine Cells.
Previous work has established that rod bipolar cell synapses are biphasic, with a transient
component that encodes increases in contrast, and a sustained component that encodes
luminance, mediated by depletion of the readily-releasable vesicle pool [122]. To investigate the
role of EAAT5-mediated inhibition in modulating signaling at this synapse, I compared the
outputs of an in-silico model of the rod bipolar – AII amacrine cell synapse when given inputs
modulated by autoinhibition as measured by the above experiments. When stimulated with
current inputs matching the responses of real cells in the presence and absence of TBOA, a
model rod bipolar without EAAT5-mediated inhibition exhibited a two-fold increase in the peak
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activation of a downstream AII amacrine cell (Figure 2.18, bottom), demonstrating that EAAT5mediated inhibition is substantial enough to act as an important modulator of signaling at this
synapse. More dramatically, I also found that local intracellular calcium ion concentration at the
rod bipolar cell pre-synapse was increased 34-fold (Figure 2.18, top).
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Figure 2.18: Outputs of in-silico model of the RBC – AII amacrine synapse.
The virtual RBC was stimulated with an excitatory input taken from the autoinhibition results in either the absence
or presence of TBOA (see Figure 2.13). Top: The local intracellular calcium ion concentration at the RBC presynapse. In our stimulus paradigm, under normal conditions, [Ca2+] peaks at only 0.46 µM. In the absence of
EAAT5-mediated inhibition, however, [Ca2+] peaks at 15.8 µM. Bottom: the excitatory post-synaptic current in the
AII amacrine cell. The control trial elicited a peak excitation of 10.5 pA, while the trial without EAAT5-mediated
inhibition peaked at 21.9 pA.
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Since this change in [Ca2+] was accompanied by a comparatively modest increase in peak AII
activation, I hypothesized that in the absence of EAAT5-mediated inhibition the model cell was
operating in the saturation plateau region of the synaptic activation curve, beyond the sensitive
range of synaptic response. To test this hypothesis, I measured the sensitivity of both models to
small changes in input amplitude and found that the output of the control model was indeed 32fold more sensitive to variation in inputs than the model lacking EAAT5 mediated inhibition
(Figure 2.19). This meant that the control cell was indeed operating along a much steeper region
of synaptic activation relative to the TBOA cell, supporting my hypothesis. Overall, these results
suggest that EAAT5-mediated autoinhibition onto rod bipolar cells may be important for gain
modulation that acts to keep the rod bipolar synapse within the more sensitive part of its
activation range.
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Figure 2.19: The synaptic sensitivity of the RBC synapse with and without EAAT5.
The inputs to each RBC were increased and decreased by 1 pA, and the resulting change in AII peak excitation was
quantified as a ratio of input current to output current, representing the sensitivity of the synapse to encode small
stimulus changes. The control cell was 32 times more sensitive than the TBOA cell. This suggests that EAAT5mediated autoinhibition keeps the RBC within the sensitive range of synaptic activation.

2.4 Discussion
This study characterizes the relative contribution of EAAT5-mediated inhibition onto rod bipolar
cells in response to physiologically relevant stimuli. It also compares the roles of EAAT5mediated autoinhibition and alloinhibition. While conventional inhibitors mediate nearly all
alloinhibition onto rod bipolar cells, EAAT5 is the primary mediator of rod bipolar
autoinhibition and may have a substantial impact on postsynaptic excitation of the downstream
AII amacrine cell. Overall, these findings greatly increase understanding of the function of
EAAT5-associated chloride channels in rod bipolar cells.
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While activation of EAAT5 by light was observed, my results do not agree with the idea of an
inhibitory switch in which EAAT5 specifically enables inhibition in response only to bright
stimuli and conventional inhibitory pathways mediate inhibition in response only to dim stimuli
[111]. Unlike the previously published work, I found EAAT-mediated inhibition across a much
broader range of light intensities. I attempted to attribute the discrepancy between the differing
results to a number of possibilities, including the wait time between cellular break-in and
beginning the experiment, presence or absence of glutamine in the extracellular media, delay
between application of flashes, thickness of the slice preparations, duration of the light stimuli,
temperature of the prep, use of dorsal vs. ventral retina, and color of the presented light, but
attempts to replicate the previously published finding by changing any of these variables were all
unsuccessful (data not shown). In the end, in order to completely assure myself of the validity of
my findings, I assayed more than ten times as many cells as the matching experiment in the cited
paper.
I have also shown that glutamate spillover likely activates EAAT5 inhibition less than previously
suggested. In the past, extensive EAAT-mediated spillover transmission in rod bipolar cells has
been reported [111], [113], but I believe these findings should be viewed with caution because,
to my knowledge, they have always depended on either excessive direct stimulation of the
neighboring cell or network-wide blockade by conventional inhibitors, which I have here
demonstrated leads to non-physiologic enhancement of EAAT5-mediated inhibition through
disinhibition of bipolar cells throughout the network. Ichinose & Lukasiewicz [111]
demonstrated that EAAT5-mediated inhibition onto rod bipolar cells is spatially limited,
consistent with the understanding that for glutamate to be released near the rod bipolar cell
synapse necessitates synaptic activity from either the cell in question or a neighboring one close
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enough to lead to spillover, which would preclude any form of long-distance lateral inhibition.
My results here are consistent with this understanding and also bring it a step further by
demonstrating that, under physiological stimulus conditions and in the absence of any exogenous
network blockade of GABA or glycine, EAAT5 does not play a major role in alloinhibition.
Nonetheless, I have demonstrated an important role for EAAT5 in rod bipolar cells:
autoinhibition. It is well-characterized that conventional autoinhibition onto rod bipolar cells is
mediated by A17 amacrine cells, which form a reciprocal GABAergic synapse with them [123],
[124]. Up to this point, however, study of total autoinhibition onto rod bipolar cells has been
neglected. This is likely because inhibitory inputs are typically studied by clamping the cell of
interest at a fixed voltage, preventing the cell’s voltage from changing and precluding glutamate
release, which necessarily eliminates EAAT5-mediated autoinhibitory effects from study.
However, my findings demonstrate that the overlooked EAAT5 inhibitory feedback pathway is
actually the most prominent source of autoinhibition in a dark-adapted rod bipolar cell.
Furthermore, my modeling data show that this inhibition is sufficient to have a substantial effect
on signal transmission through the rod bipolar – AII synapse and may be acting to keep the rod
bipolar cell within the sensitive part of its activation curve.
Because autoinhibition does not include input from parallel pathways, it cannot carry spatial
information, but rather must mediate temporal processing. In particular, I speculate that
autoinhibition in the rod bipolar cell specifically acts as a gain modulator, allowing the cell to
transmit sudden changes in signaling intensity, but acting as negative feedback to push the cell
back towards an equilibrium in response to longer stimuli. In addition, complex control over this
filtering effect could be effectively accomplished by separate mechanisms with differing
kinetics. EAAT-mediated inhibition onto rod bipolar cells is known to have slower kinetics than
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conventional inhibition [110], [111]. This suggests that EAAT5-mediated inhibition may be
acting in concert with conventional A17-mediated autoinhibition to define a sophisticated
temporal gain modulator.
In particular, at very low light intensities, the delayed autoinhibition from EAAT5 may act to
enhance the relatively slow single-photon signal in the rod pathway. At low light intensities
(around 10-3 – 10-1 photons/µm2/s), the rod bipolar cell is tuned to transmit single photon signals
from rods. Others have shown that the transient timing of the rod bipolar vesicle release function
is the correct duration to pass a single photon signal [27], [122]. EAAT5 autoinhibition may be
just delayed enough to allow the single-photon transient to pass, and then inhibit the rod bipolar
cell to counter long-term baseline depolarization. Thus, by regulating the baseline slowly,
EAAT5 autoinhibition may prevent depletion of the readily-releasable pool and maintain the
right level to depolarization to allow single-photon signals to be transmitted. At medium
backgrounds (around 10-1 – 102 photons/µm2/s), EAAT5 autoinhibition may instead be acting to
allow the contrast encoding described by Oesch and Diamond [122]. At brighter backgrounds
than that, rod bipolar cells are highly depolarized (20 – 30 mV above their dark resting level),
and their Ca2+ channels are likely to be inactivated when depolarized that far.
Overall, this study increases understanding of the roles of EAATs in the retina. The removal of
glutamate from retinal synapses is primarily performed by EAAT1, also known as GLAST, on
Müller glial cells [125]–[127]. EAAT2 and EAAT3, which can be found on retinal neurons, are
similarly biased towards glutamate transport and exhibit very little chloride conductance but
appear to have a much smaller role in bulk removal of glutamate from synapses [127], [128].
EAAT5, on the other hand, plays almost no role in glutamate transport [86], [109], but instead
mediates autoinhibition in rod bipolar cells, and likely plays the same role in photoreceptors as
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well. EAAT4 has a high-affinity glutamate-gated chloride activity similar to EAAT5, but is
primarily expressed in the cerebellum [64], where it may be acting similarly to EAAT5 in the
retina.
Gain modulation in sensory-system neurons is important for transmitting information on
stimulus changes despite a wide range of baseline stimulus intensities, and the glutamateactivated inhibition of EAAT5 makes it a natural candidate for gain modulation. My data
supports the idea that EAAT5 is playing this role at the rod bipolar synapse.
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Chapter 3: Functional Deficits Precede
Structural Lesions in Diabetic Retinopathy
3.1 Background
Diabetic retinopathy is an end-organ complication of either type 1 or type 2 diabetes mellitus
[87]. It is commonly understood to be the result of damage to the microvasculature and neurons
of the retina, and is a leading cause of blindness worldwide [88]. Its prevalence is increasing at
an alarming rate, particularly in developed countries where the incidence of type II diabetes has
been rapidly increasing, likely due to the current epidemic of obesity and overnutrition. The
National Eye Institute projects that more than 14.6 million Americans alone will have diabetic
retinopathy by the year 2050 [129]. It can take many years for a diabetic patient to develop
symptoms of retinopathy, but patients can progress quite rapidly to blindness once symptoms
appear [89]. Disease progression involves vascular endothelial growth factor (VEGF), and antiVEGF therapy is commonly used in diabetes care [130], [131]. However, anti-VEGF agents
require prolonged frequent administration, are not always effective, and may have adverse
effects [132]. Long-term VEGF antagonism in mice may induce vision loss [133]. On the other
hand, other treatments for diabetic retinopathy are also associated with serious adverse effects
[134]. There is a critical need for a better understanding of the basic pathogenic mechanisms of
this disease.
The traditional understanding of diabetic retinopathy is that diabetes causes vascular leakage and
edema in the retina which in turn leads to neuronal damage and loss of vision. Thus, diabetic
retinopathy is treated clinically with drugs and procedures aimed at reducing vascular leakage,
proliferation, and edema. However, deficits in the oscillatory potential (OP) component of the
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electroretinogram (ERG) have been observed in retinas of both patients and diabetic animal
models [135]. Oscillatory potentials represent processing in the inner retina and have been
attributed to amacrine cells and ganglion cells [136]. Conversely, the ERG components that
represent photoreceptor and bipolar cell function are unchanged when inner retinal defects are
first detected. In morphological studies, diabetic mice lose several classes of amacrine and
ganglion cells via apoptosis [137], [138]. Apoptotic losses, however, occur months after diabetes
onset, whereas functional defects in these neurons can be observed within weeks [135],
suggesting that early deficits of neuronal signaling or integration may possibly precede more
severe changes.
In the clinic, diabetic patients are typically first seen and treated when they present with signs
and symptoms attributable to retinal vascular pathology; electrophysiological visual testing is not
regularly used to assess diabetic patients [95], [96]. Thus, a better understanding of the neuronal
deficits in the early-stage diabetic retina may lead to earlier intervention and prevention of later
vascularization, edema, and blindness.
A number of rodent models have been developed and used for the study of diabetic retinopathy
[139]. Genetic models will spontaneously develop diabetes; commonly used genetic models
include the Ins2Akita mouse, a model of type 1 diabetes in which insulin deficiency results from a
point mutation in the Insulin-2 gene, and the db/db mouse, a model of type 2 diabetes that lacks
the leptin receptor, which leads to overfeeding, obesity, and insulin resistance [140], [141]. The
neurotoxin streptozotocin as also widely used to induce beta cell loss and subsequent insulin
deficiency to model type 1 diabetes in wild-type rodents [142]. Each of these approaches has
important limitations, however. In general, single-locus genetic models such as the db/db and
Ins2Akita mice fail to represent the true multifactorial nature of human diabetes. Rather, some
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elements of their pathology may be unrelated to diabetes but instead to the consequences of their
underlying genetic alteration. More specifically, the Ins2Akita mouse is generally reflective of the
overall physiology of type 1 diabetes but Ins2Akita mice do not develop retinopathy [143], and
leptin signaling affects the retina [144], suggesting that db/db mice are not an ideal model for
obesity-related diabetic retinopathy. Meanwhile, streptozotocin is used as a model for type 1
diabetes because it directly kills pancreatic β-cells and causes rapid diabetic disease, but it also
has off-target effects including immunosuppression [145], nephrotoxicity [146], hepatotoxicity
[147], and neurotoxicity [148]–[150]. The undesired toxic effect on neuronal tissue obviously
confounds the interpretation of retinal changes. In addition, streptozotocin-treated mice do not
require insulin for survival, unlike humans with type 1 diabetes.
Another animal model is the high-fat diet obese mouse. Rodents fed a diet of 42% fat develop
weight gain and subsequent insulin resistance and diabetes [151], which better reflects human
obesity-related type 2 diabetes. Animals fed the high-fat diet developed hyperinsulinemia that
peaked at 6 months of age and was less marked by 12 months (Figure 3.1). This pattern likely
reflects initial beta-cell hypersecretion, followed by beta-cell dysfunction and loss mirroring the
progression of human type 2 diabetes. Until recently, these mice had not been studied
systematically for diabetic retinopathy, but these animals do in fact develop eye disease [152].
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Figure 3.1: High-fat diet fed mice develop obesity and glucose intolerance.
(Figure taken from [152].) Male C57BL/6J mice were fed standard chow or a high-fat diet providing 42% of energy
from fat. Insulin levels from fasting serum samples were measured using an ELISA-based method at 3, 6, and 12
months of age. Values represent mean ± SEM from at least five independent experiments in each group. ****P <
0.0001.

In human non-proliferative diabetic retinopathy, vascular signs such as intraretinal microvascular
anomalies, venous beading, dot-blot hemorrhages, and microaneurysms are detectable by
ophthalmoscopy. In diabetic rodents, the equivalent identifiable pathologic features are capillary
basement membrane thickening, atrophy of small capillaries, and a loss of pericytes known
histologically as “pericyte ghosts” [139]. When retinas were flat mounted and trypsin-digested to
stain for microvessel skeletons, there were no differences in the mean number of atrophic
capillaries or pericyte ghosts between high-fat diet and chow-fed mice at 6 months of age (Figure
3.2). However, at 12 months of age high-fat diet animals showed more atrophic capillaries and
pericyte ghosts compared with controls [152].
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Figure 3.2: At an advanced age, high-fat diet fed mice develop typical lesions of diabetic retinopathy.
(Figure taken from [152].) Retinal vasculature networks were analyzed in 6- and 12-month-old animals by trypsin
digest of isolated and fixed retinas, followed by periodic acid Schiff/hematoxylin staining. High-fat diet fed animals
develop significantly more atrophic capillaries (left) and pericyte ghosts (right) at 12 months, but not 6 months, of
age, compared with chow-fed controls. Shown are quantifications of vascular lesions, as assessed by a masked
grader. Values represent mean ± SEM from 10 independent experiments in each group. **P < 0.01, ***P < 0.001 by
ANOVA.

Evans Blue dye is commonly used as a vascular permeability assay. In normal controls, Evans
Blue dye injected into the bloodstream stays within the plasma compartment for hours, but in
experimental diabetes, Evans Blue dye leakage is detectable in the vitreous and neural retina
[153]. High-fat diet fed animals have more Evans Blue leakage into the aqueous compartment
than controls at 12 months but not 6 months (Figure 3.3) [152].
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Figure 3.3: High-fat diet feeding promotes retinal vascular permeability.
(Figure taken from [152].) Evans Blue dye (25 mg/kg) was injected intravenously into anesthetized animals and
allowed to circulate for 180 minutes. Quantification of dye fluorescence from aqueous paracentesis samples
demonstrates significantly greater leakage in high-fat diet fed animals compared with controls at 12 months of age
but not at 6 months of age. Values represent mean ± SEM. *P < 0.05 by ANOVA.

Here I perform electroretinography on high-fat diet mice over time to determine the sequence of
vascular and neurologic dysfunction in diabetes induced by feeding without administration of a
potential neurotoxin. My findings show that high-fat diet feeding produces retinopathy in which
neurologic dysfunction precedes vascular dysfunction.

3.2 Materials and Methods
3.2.1 Animals
Protocols followed the Association for Research in Vision and Ophthalmology Statement for the
Use of Animals and were approved by Washington University in St. Louis. C57BL/6J mice were
free of RD1 or RD8 mutations. Animals were weaned onto Purina 4043 chow (13% kcal from
fat, 62% kcal from carbohydrate, 25% kcal from protein) or Harlan Teklad TD 88137 HFD (42%
kcal from fat, 43% kcal from carbohydrate, and 15% kcal from protein).
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3.2.2 Electroretinography
A UTAS BigShot System (LKC Technologies, Inc., Gaithersburg, MD) was used. Mice (≥5 for
each group) were dark adapted overnight. Under red light illumination, animals were
anesthetized with ketamine (80 mg/kg total body mass) and xylazine (15 mg/kg lean body mass).
Pupils were dilated with 1% atropine sulfate. Body temperature was maintained at 37°C with a
heating pad. Contact lens electrodes were placed bilaterally with appropriate reference and
ground electrodes.
The stimulus consisted of a full-field white light flash (10 µs) in darkness or in the presence of
dim (30.0 candela [cd]/m2) background illumination after 10 min adaptation time. The response
was recorded over 231 ms plus 25 ms of pretrial baseline. Between 5 and 10 repeated trials were
averaged for each luminance, with 10 repeats used for the dimmest flashes, and 5 for the
brightest. Raw data were processed using MATLAB software (MathWorks, Natick, MA). The
amplitude of the a-wave was measured from the average pretrial baseline to the most negative
point of the average trace, and the b-wave amplitude was measured from that point to the highest
positive point, after subtracting oscillatory potentials (OPs). The eye with the larger recorded bwave amplitude was used for each mouse. OPs were isolated using a digital Butterworth 25 Hz
high-pass filter and quantified using root-mean-square analysis of filtered waves, normalized to
the maximal b-wave amplitude. The log luminance of the stimulus (log [cd · s/m2]) was
calculated based on the manufacturer's calibrations.

3.2.2 Statistical Analysis
Distributions of electroretinography (ERG) responses across diet groups at different light
intensities are described by means ± SEM. Differences were compared using two-way ANOVA,
followed by a Bonferroni post hoc test for multiple comparisons.
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3.3 Results
Although the primary clinical hallmark of diabetic retinopathy is vascular disease, antecedent or
coincident electrophysiological changes also occur in humans [94], [154]–[156]. It is less clear
whether neural effects are involved in the etiology of diabetic retinopathy in rodents. To
determine whether neurologic dysfunction occurs early in high-fat diet-induced diabetic
retinopathy, I performed full-field, stimulus-evoked scotopic and photopic electroretinograms
(ERGs) in high-fat diet fed mice and chow-fed controls.
After dark adaption overnight, scotopic ERG was performed with full-field white stimulus given
across increasing intensities. Thereafter, a 10-minute period of light adaptation was performed
against a dim white background of 30-cd/m2 luminance. Photopic ERG was recorded at
increasing stimulus intensities. Raw ERG data were then analyzed for a-wave (scotopic reading
only) and b-wave (in both scotopic and photopic conditions) amplitudes and implicit times. The
raw waves were processed through a digital high-pass filter to isolate early oscillatory potentials
(OPs), as shown in Figure 3.4.

Figure 3.4: ERG analysis parameters.
ERG responses were recorded from animals in scotopic conditions after overnight dark adaptation. A high-pass filter
was applied to the raw ERG to isolate the OPs for separate analysis from the a-wave and b-wave measurements.
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As expected, maximal ERG responses to white light stimuli for both a-waves and b-waves
declined with age (Figure 3.5). At no age did I observe a difference in amplitudes or implicit
times in scotopic a-waves or b-waves between HFD and control groups. There were no
differences in photopic b-wave characteristics between different groups at any age (data not
shown).
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Figure 3.5: High-fat diet feeding does not alter major retinal responses to light stimuli.
ERG responses were recorded from animals in scotopic conditions after overnight dark adaptation. ERG a-wave
amplitudes recorded at 3, 6, and 12 months of age are plotted against stimulus luminance (left), with corresponding
b-wave amplitudes (right). Values represent the mean ± SEM from at least five animals at each age. Decline in
amplitudes of responses are seen with increasing age. At all tested ages, no significant differences were observed
between animals on different diets with regard to either major ERG component (ANOVA).

Amplitudes of summed OPs did not differ between dietary groups at 3 or 6 months of age
(Figures 3.6, top and 3.7, top). However, at 12 months of age, average OP amplitudes were
49

significantly reduced in HFD-fed animals compared with chow-fed controls at all stimulus
intensities (P < 0.05) except for the dimmest (−2.4 log [cd · s/m2]) and brightest (0.89 log [cd ·
s/m2]) (Figure 3.8, top). Examples of the preferential decline in OP amplitudes in HFD-fed
animals compared with controls, with relative preservation of a-wave and b-wave amplitudes, are
shown in Figure 3.9.

Figure 3.6: Three-month high-fat diet fed mice do not have decreased OP amplitudes.
Visual function in high fat diet or chow-fed animals was assessed at 3 months of age by ERG under scotopic, darkadapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP
amplitudes are plotted against stimulus luminance at 3 months of age (top). Values represent the mean ± SEM from
at least five animals. Bottom: Correlation plot of normalized OP amplitude with the area under the curve (AUC) for
the intraperitoneal glucose tolerance test (GTT) are shown for animals at 3 months of age. Each data point represents
a unique animal. Pearson correlation analyses were performed for animals fed each diet at each tested age, with R2
and P values shown.
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Figure 3.7: Six-month high-fat diet fed mice do not have decreased OP amplitudes.
Visual function in high-fat diet or chow-fed animals was assessed at 6 months of age by ERG under scotopic, darkadapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP
amplitudes are plotted against stimulus luminance at 6 months of age (top). Values represent the mean ± SEM from
at least five animals. Bottom: Reductions in OP amplitudes correlate with glucose intolerance beginning at 6 months
of age. Correlation plots of normalized OP amplitude with the area under the curve (AUC) for the intraperitoneal
glucose tolerance test (GTT) are shown for animals at 6 months of age. Each data point represents a unique animal.
Pearson correlation analyses were performed for animals fed each diet, with R2 and P values shown.
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Figure 3.8: Twelve-month high-fat diet fed mice have decreased OP amplitudes.
Visual function in high-fat diet or chow-fed animals was assessed at 12 months of age by ERG under scotopic, darkadapted conditions. OPs were extracted from the raw ERG trace using a high-pass filter. The root mean square
(RMS) of all OP peaks and troughs were normalized to the amplitude of the maximal b wave. RMS of OP
amplitudes are plotted against stimulus luminance at 12 months of age (top). At 12 months of age, mice fed the HFD
demonstrate significant declines in OP amplitudes relative to controls. Values represent the mean ± SEM from at
least five animals. *P < 0.05 by ANOVA. Bottom: Reductions in OP amplitudes correlate with glucose intolerance
beginning at 6 months of age and continuing at 12 months. Correlation plots of normalized OP amplitude with the
area under the curve (AUC) for the intraperitoneal glucose tolerance test (GTT) are shown for animals at 12 months
of age. Each data point represents a unique animal. Pearson correlation analyses were performed for animals fed
each diet at each tested age, with R2 and P values shown in the lower right corner of each graph.
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Figure 3.9: Twelve-month high-fat diet mice have decreased OP amplitudes: Example traces.
Visual function in high-fat diet or chow-fed animals was assessed by ERG under scotopic, dark-adapted conditions.
OPs were extracted from the raw ERG trace using a high-pass filter. Representative ERG tracings from mice fed
each of the two indicated diets are shown, with the HFD-fed mice displaying reductions in OP amplitudes compared
with chow-fed controls.

HFD feeding promotes insulin resistance, but individual mice show variable glucose tolerance
responses. To determine whether mice with greater glucose intolerance (i.e., higher area under
the curve values during a glucose tolerance test) also have a greater reduction in OP amplitudes,
we correlated OP amplitudes with area under the curve of the glucose tolerance test for
individual mice at different ages. At 3 months (Figure 3.6, bottom), no correlation was found
between glucose tolerance and OP amplitudes in either dietary group. However, at 6 months
(Figure 3.7, bottom), the area under the curve of the glucose tolerance test was correlated with
lower OP amplitudes in the high-fat diet group (Pearson R2 = 0.60, P = 0.04). In contrast, no
such correlation was found for chow-fed animals of the same age (R2 = 0.02, P = 0.81). At 12
months (Figure 3.8, bottom), the correlation between glucose tolerance and lower OP amplitudes
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was also present in high-fat diet animals (Pearson R2 = 0.51, P = 0.009) but not in chow-fed
controls (R2 = 0.12, P = 0.5).
Prompted by this correlation, I determined whether OP kinetics may be affected in the high-fat
diet-induced diabetes model by measuring the latency time for each of the first four OPs
recorded on scotopic ERG at 3, 6, and 12 months (Figure 3.10). Beginning at 6 months of age, a
significant delay in implicit time for the first two OPs (OP1 and OP2) elicited by a −0.60 log (cd
· s/m2) white light flash was observed in HFD-fed animals (27.1 ± 2.2 ms) compared with
controls (24.3 ± 1.8) at OP1 (P < 0.05). This delay persisted through 12 months, with an average
OP1 implicit time of 25.6 ± 2.0 ms in high-fat diet fed animals compared with 24.2 ± 1.4 ms in
chow-fed controls (P < 0.05) and an average OP2 implicit time of 32.0 ± 2.6 ms in high-fat diet
fed animals compared with 30.5 ± 1.9 ms in chow-fed controls (P < 0.05). These data are
consistent with the notion that diet-induced insulin resistance promotes early neurologic deficits
in the retina. By ERG analysis, these deficits are manifested as reductions in amplitude and
delays in OP responses to white light stimuli under scotopic conditions. Thus, electrophysiologic
abnormalities detected at 6 months precede the development of vascular abnormalities at 12
months (Figures 3.2 and 3.3) in a diabetes model induced by a clinically relevant diet without
genetic manipulations or administration of toxins.
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Figure 3.10: Delays in OP implicit times are seen in high-fat diet animals before development of vascular lesions.
Implicit times of the first four OPs (OP1–4) were measured from ERGs generated by a 0.25 cd · s/m2 white light
stimulus. Recordings were performed at each indicated age. At 6 months of age, HFD-fed mice show significant
delays in the implicit times of the first two OP peaks compared with chow-fed mice. This difference persists through
12 months of age. Shown are mean values ± SEM for each of the four measured peaks, with individual values for
each animal tested superimposed (at least five animals were used in each diet group at each age). *P < 0.05 by
ANOVA.
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3.4 Discussion
Neurologic activity in the retina is metabolically demanding [157], and it is not surprising that
retinal neural function might be altered in diabetes. Nevertheless, diabetic retinopathy is
considered first and foremost a disease of blood vessels. In humans and mice, the earliest visible
signs of the disease are generally believed to be vascular. Because of this, it has largely been
assumed that early neural insults are resultant from vascular damage in the retina. However, in
this chapter, I demonstrate in an animal model that in diet-induced diabetes retinal function is
disturbed before the development of detectable defects in the retinal vasculature.
Using a clinically relevant diet, it has been shown that the development of obesity, glucose
intolerance, and insulin resistance in mice is associated with pericyte damage and microvascular
atrophy by 1 year of age [152]. Using ERG, I show that a functional neurologic deficit occurs by
6 months, before vascular injury. This functional abnormality is correlated with glucose
intolerance and persists to 12 months.
This work is novel because the relationship between early ERG dysfunction and retinopathy
development is confounded in other mouse models. In the streptozotocin diabetes model, ERG
and structural vascular abnormalities have both been identified [158]–[160], but streptozotocin
causes off-target neurologic effects [149], [150]. Streptozotocin also causes rapid onset of severe
disease that obscures any potential early neural contribution. In the db/db mouse, which develops
a disease more similar to type 2 diabetes due to leptin receptor deficiency, massive reductions in
b-wave amplitude have been recorded at around 6 months of age [161], but these findings
coincide with vascular defects, including morphological abnormalities and abnormal leakage.
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Leptin signaling also has trophic and angiogenic effects in the retina that could have accounted
for the ERG deficits seen in these mice [144]. Diet-induced metabolic disease in rodents has
been shown to produce retinal inflammation and degeneration [162], [163], and a rat model of
type 2 diabetes manifests features of retinal inflammation and vascular disease coincident with
severe metabolic derangements [164], but these studies did not report ERG responses.
The high-fat diet model is a slow-onset disease, accurately representing the pathophysiology of
human type 2 diabetes complications such as retinopathy. Even after 1 year, high-fat diet mice
do not lose inner retinal thickness [152], confirming that disease in these animals is mild and
similar to the early stages of human retinopathy [165], [166]. My findings that OP disturbances
precede the appearance of vascular disease are consistent with data from humans, where
electrophysiology is altered prior to visible microvascular disease, frequently involving the same
specific waveforms [155], [167].
The ERG changes shown here are small but extremely specific to OPs. Unlike the large ERG
effects caused by mutations in visual cycle proteins, ERG changes in diabetes are expected to be
modest. Full-field ERG represents a summed response of the neural retina to light. However, just
like in human diabetic retinopathy, I would not expect experimentally induced rodent retinopathy
to be uniform. In humans, multifocal ERG identifies preferentially affected regions that later
develop classic vascular lesions of retinopathy [93], [168], but unfortunately multifocal
recording was not possible in rodents as of the time this work was performed. Compared to
visual function assays, structural and functional assays of blood vessel integrity offer more
specificity due to greater spatial resolution. Given the relatively lower resolution for full-field
ERG in mice, it is therefore meaningful that functional deficits correlated with glucose
intolerance precede the detection of vascular defects, since I would surmise that a detection bias
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would likely work in favor of histology, not ERG. It is also known that OP characteristics can
lead to artifacts in b-wave recordings [169], [170], but I did not detect b-wave changes between
groups, so this potential confounder is not an issue here.
Distorted OPs are believed to represent perturbations of the inner retina, specifically
dysfunctional amacrine, bipolar, and retinal ganglion cells [171], [172]. Thus, my findings
suggest that inner retinal networks may be important early targets of diabetic disease.
It is of course possible that early ERG dysfunction in humans and mice could be caused by
microvascular disease that cannot be detected with current technologies. Alternatively, dietinduced diabetes may disturb neuroglial-vascular coupling. Neurovascular coupling is mediated
by VEGF, semaphorin 3a, nitric oxide, and arachidonic acid metabolites, all of which are known
to be affected by diabetes [173]–[176]. Nevertheless, my findings in this chapter are only
correlative. Additional studies are required to demonstrate how high-fat diet-induced diabetes
affects interactions between neurons and vasculature. I believe the high-fat diet mouse model
will continue to be useful for studying the interactions between early neuronal, glial, and
neurovascular changes in diabetic retinopathy. Doing so will be important, because finding new
targets or biomarkers in the high-fat diet model may accelerate the improvement of clinical
interventions for this debilitating disease.
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Chapter 4: Summary and Future Directions
4.1 EAAT5
In Chapter 2, I demonstrated the relative contribution of EAAT5-mediated inhibition onto rod
bipolar cells in response to physiologically relevant stimuli in retinal slice explants. In this
setting, I also compared the roles of autoinhibition, in which excitation of the cell leads to
inhibition onto itself, and alloinhibition, which is driven by other bipolar cells. Contrary to prior
reports, I found that EAAT5-mediated inhibition can be elicited by dim light stimuli. I also found
that while conventional inhibitors mediate nearly all alloinhibition onto rod bipolar cells, EAAT5
is the primary mediator of rod bipolar autoinhibition. Finally, in silico modeling demonstrated
that EAAT5-mediated autoinhibition may have a substantial impact on postsynaptic excitation of
the downstream AII amacrine cell.
I speculated that autoinhibition in the rod bipolar cell may specifically act as a gain modulator,
allowing the cell to transmit sudden changes in signaling intensity, but acting as negative
feedback to push the cell back towards an equilibrium in response to longer stimuli. In particular,
I hypothesized that EAAT-mediated inhibition onto rod bipolar cells may have the correct
kinetics to enhance the relatively slow single-photon signal in the rod pathway at very low light
intensities. While my data fit this hypothesis, it still requires experimental validation, and further
work to investigate this question is warranted. Future experiments should present retinas with
extremely dim stimuli in the presence and absence of EAAT5-mediated inhibition. If the
hypothesis is correct, single-photon stimuli should cause a longer period of depolarization in the
absence of EAAT5, such that the threshold for detection of an initial single-photon stimulus is
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unchanged, but the downstream AII amacrine cell is better able to resolve sequential singlephoton excitations with EAAT5-mediated inhibition at the rod bipolar cell intact.
Of course, this also raises the question of how the EAAT5 system responds to light adaptation
more generally. While my work here did investigate responses to varying intensities of light, the
stimuli presented here were in the context of a pure black background, on completely darkadapted preparations. I have done some experiments (not shown) with light-adapted
preparations, but these were grossly light-adapted into the low photopic range, where rod bipolar
cells will be highly depolarized even at baseline and their Ca2+ channels will be largely
inactivated, eliminating autoinhibition. I have not done any experiments in which rod bipolar
cells were more subtly light-adapted, to around 0.1 photons/µm2/s, for example. Repeating under
such conditions the kind of experiments I have performed here would be quite informative in
investigating the role that EAAT5 may play in light adaptation.
All of these studies, and more, would also be greatly facilitated by the development of a bipolarcell specific genetic knockout of EAAT5. During the time I have done the work presented here,
the only available EAAT5 mutants were constitutive knockouts, and since EAAT5 is also present
in photoreceptors, such mice were not useful for light-stimulus experiments. However, genetic
technologies have progressed to the point where it should now be fairly straightforward to
generate an EAAT5 selective knockout driven by a bipolar cell specific promoter. Such a model
would provide a valuable check on my conclusions here, and also a valuable tool for further
experiments. A genetic paradigm would also allow for more global assays of the effects of
EAAT5, including experiments to assess the role of EAAT5-mediated inhibition on visual
parameters like visual sensitivity and contrast sensitivity, which can be assessed using
optokinetic reflex or water maze behavioral testing or ganglion cell recording experiments.
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Finally, while the findings of this work have elucidated the function of EAAT5 in the inner
retina specifically, it is likely that it may have general implications for other neurotransmitter
transporters that can act as ion channels elsewhere. In particular, the closely-related EAAT4 is
already known to have a glutamate-gated chloride conductance similar to that of EAAT5 and is
also known to be found in neuronal axon terminals – in this case in cerebellar Purkinje cells.
Future studies should investigate whether EAAT4 is playing the same functional role in the
cerebellum that EAAT5 is in the inner retina.

4.2 Diabetic Retinopathy
In Chapter 3, I characterized the course of electroretinographic dysfunction in a high-fat diet–
induced model of diabetes in mice. Mice weaned to chow or to a high-fat diet were tested for
electroretinographic dysfunction at 3, 6 and 12 months of age. There was no evidence of
microvascular disease in these mice until 12 months. However, at as early as 6 months, high fat
fed mice demonstrated increased latencies and reduced amplitudes of oscillatory potentials (a
marker reflective of inner retinal neurons) when compared with controls. These
electroretinographic abnormalities were correlated with glucose intolerance.
The results suggest that disease in the diabetic milieu may progress through neuronal stages in
the inner retina long before the development of vascular lesions representing the classic hallmark
of diabetic retinopathy. However, the neuronal types and the cellular and synaptic processes
involved in the functional deficits are unknown. Identifying these components could possibly
lead to novel interventions to treat eye disease.
When action potentials in the retina are blocked with tetrodotoxin, oscillatory potentials are
reduced [177], [178]. This suggests that oscillatory potentials represent the contributions of
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spiking neurons, meaning amacrine cells, ganglion cells, or both. Thus, action potentials may be
compromised in amacrine or ganglion cells in the early stages of diabetic retinopathy. To
determine whether this is the case, and, if so, which cells, future work should compare spiking
activity in ganglion cells and spiking amacrine cells in high-fat diet and control mice. This
should be feasible to do via single-cell patch-clamp recordings like those used here in Chapter 2.
If changes in innate spiking ability are observed, it should then be possible to further isolate the
specific molecular changes involved by comparing the activation and inactivation properties of
pharmacologically-isolated sodium and potassium channels in these cells.
Alternatively, it may be that altered inputs to amacrine or ganglion cells are responsible for the
changes in ERGs I have observed here. For example, reduced excitatory input or increased
inhibitory input to ganglion cells may lead to the reduced oscillatory potentials seen here. Future
work should also investigate this possibility, by comparing the light-evoked excitatory or
inhibitory post-synaptic currents onto ganglion cells from high-fat diet and control mice. From
there, changes can be further narrowed down to changes in neurotransmitter release versus
changes in receptor responsiveness by comparing the effects of paired pulse protocols versus the
effects of spontaneous postsynaptic current recordings.
Of course, the question of whether or not the early electrical changes observed in these mice
actually precede or coincide with changes in visual function also remains. In humans, data has
demonstrated that changes in the ERG oscillatory potential precede measurable visual loss [90]–
[94]. If this is the case, the high-fat diet model would be most clinically useful if it also
recapitulates this aspect of disease. Future work should assess the visual function of high-fat diet
mice versus controls using visual parameters like contrast detection, spatial resolution, temporal
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resolution, and light adaptation, which can all potentially be assessed using optokinetic reflex or
water maze behavioral testing.
Finally, future work should investigate the possibility that electroretinographic testing could
become more routinely used to screen for retinopathy in diabetic patients. First in patients, and
now in mice, it has been shown that the oscillatory potential is a very early marker of disease
progression that precedes the development of vascular changes in the retina. Clinically, however,
routine screening is almost exclusively funduscopic, meaning that patients are not detected as
having retinopathy until vascular changes have already begun. Perhaps because oscillatory
potentials are a relatively obscure parameter compared to a-waves and b-waves, and because
current treatments are geared toward halting vascular progression anyway, electroretinographic
screening is not typically used. Indeed, it may not yet be practical to screen patients with ERGs
in the general diabetic population, but researchers studying retinopathy therapeutics may benefit
from ERG testing to identify the development of retinopathy in clinical study populations, which
could, in itself, lead to the development of therapeutics that can be used in the earliest stages to
prevent retinopathy progression. Thus, there is the potential for great clinical benefit if these
findings can be leveraged to detect retinopathy in patients at an earlier stage.
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